Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

NCT02760602 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02760602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02760602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2016
Completion date
May 31, 2017
Enrollment
26 (actual)
Sites
193

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease